Your browser doesn't support javascript.
loading
De novo variants of CSNK2B cause a new intellectual disability-craniodigital syndrome by disrupting the canonical Wnt signaling pathway.
Asif, Maria; Kaygusuz, Emrah; Shinawi, Marwan; Nickelsen, Anna; Hsieh, Tzung-Chien; Wagle, Prerana; Budde, Birgit S; Hochscherf, Jennifer; Abdullah, Uzma; Höning, Stefan; Nienberg, Christian; Lindenblatt, Dirk; Noegel, Angelika A; Altmüller, Janine; Thiele, Holger; Motameny, Susanne; Fleischer, Nicole; Segal, Idan; Pais, Lynn; Tinschert, Sigrid; Samra, Nadra Nasser; Savatt, Juliann M; Rudy, Natasha L; De Luca, Chiara; White, Susan M; Krawitz, Peter; Hurst, Anna C E; Niefind, Karsten; Jose, Joachim; Brancati, Francesco; Nürnberg, Peter; Hussain, Muhammad Sajid.
Affiliation
  • Asif M; Cologne Center for Genomics (CCG), University of Cologne, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany.
  • Kaygusuz E; Center for Biochemistry, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
  • Shinawi M; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany.
  • Nickelsen A; Center for Biochemistry, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
  • Hsieh TC; Bilecik Seyh Edebali University, Molecular Biology and Genetics, Gülümbe Campus, 11230 Bilecik, Turkey.
  • Wagle P; Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.
  • Budde BS; Institute of Pharmaceutical and Medicinal Chemistry, Westphalian Wilhelms-University, Münster, Germany.
  • Hochscherf J; Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Rheinische Friedrich Wilhelms, Universität Bonn, Bonn, Germany.
  • Abdullah U; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
  • Höning S; Cologne Center for Genomics (CCG), University of Cologne, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany.
  • Nienberg C; Department of Chemistry, Institute of Biochemistry, University of Cologne, Cologne, Germany.
  • Lindenblatt D; University Institute of Biochemistry and Biotechnology (UIBB), PMAS-Arid Agriculture University, Rawalpindi, Pakistan.
  • Noegel AA; Center for Biochemistry, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
  • Altmüller J; Institute of Pharmaceutical and Medicinal Chemistry, Westphalian Wilhelms-University, Münster, Germany.
  • Thiele H; Department of Chemistry, Institute of Biochemistry, University of Cologne, Cologne, Germany.
  • Motameny S; Center for Biochemistry, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
  • Fleischer N; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany.
  • Segal I; Cologne Center for Genomics (CCG), University of Cologne, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany.
  • Pais L; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Core Facility Genomics, Charitéplatz 1, 10117 Berlin, Germany.
  • Tinschert S; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
  • Samra NN; Cologne Center for Genomics (CCG), University of Cologne, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany.
  • Savatt JM; Cologne Center for Genomics (CCG), University of Cologne, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany.
  • Rudy NL; FDNA Inc., Boston, MA, USA.
  • De Luca C; Hospital Center, Safed, Israel.
  • Paola Fortugno; Zentrum Medizinische Genetik, Medizinische Universität, Innsbruck, Austria.
  • White SM; Hospital Center, Safed, Israel.
  • Krawitz P; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Hurst ACE; Genomic Medicine Institute, Geisinger, Danville, PA, USA.
  • Niefind K; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Jose J; Department of Life, Health and Environmental Science, University of L'Aquila, 67100 L'Aquila, Italy.
  • Nürnberg P; Department of Life, Health and Environmental Science, University of L'Aquila, 67100 L'Aquila, Italy.
  • Hussain MS; IRCCS, San Raffaele Roma, 00163 Roma, Italy.
HGG Adv ; 3(3): 100111, 2022 Jul 14.
Article in En | MEDLINE | ID: mdl-35571680
CSNK2B encodes for casein kinase II subunit beta (CK2ß), the regulatory subunit of casein kinase II (CK2), which is known to mediate diverse cellular pathways. Variants in this gene have been recently identified as a cause of Poirier-Bienvenu neurodevelopmental syndrome (POBINDS), but functional evidence is sparse. Here, we report five unrelated individuals: two of them manifesting POBINDS, while three are identified to segregate a new intellectual disability-craniodigital syndrome (IDCS), distinct from POBINDS. The three IDCS individuals carried two different de novo missense variants affecting the same codon of CSNK2B. Both variants, NP_001311.3; p.Asp32His and NP_001311.3; p.Asp32Asn, lead to an upregulation of CSNK2B expression at transcript and protein level, along with global dysregulation of canonical Wnt signaling. We found impaired interaction of the two key players DVL3 and ß-catenin with mutated CK2ß. The variants compromise the kinase activity of CK2 as evident by a marked reduction of phosphorylated ß-catenin and consequent absence of active ß-catenin inside nuclei of the patient-derived lymphoblastoid cell lines (LCLs). In line with these findings, whole-transcriptome profiling of patient-derived LCLs harboring the NP_001311.3; p.Asp32His variant confirmed a marked difference in expression of genes involved in the Wnt signaling pathway. In addition, whole-phosphoproteome analysis of the LCLs of the same subject showed absence of phosphorylation for 313 putative CK2 substrates, enriched in the regulation of nuclear ß-catenin and transcription of the target genes. Our findings suggest that discrete variants in CSNK2B cause dominant-negative perturbation of the canonical Wnt signaling pathway, leading to a new craniodigital syndrome distinguishable from POBINDS.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: HGG Adv Year: 2022 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: HGG Adv Year: 2022 Type: Article Affiliation country: Germany